WO1999065526A1 - Composition d'onguent s'utilisant en application locale pour traiter les brulures - Google Patents
Composition d'onguent s'utilisant en application locale pour traiter les brulures Download PDFInfo
- Publication number
- WO1999065526A1 WO1999065526A1 PCT/BR1998/000031 BR9800031W WO9965526A1 WO 1999065526 A1 WO1999065526 A1 WO 1999065526A1 BR 9800031 W BR9800031 W BR 9800031W WO 9965526 A1 WO9965526 A1 WO 9965526A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fact
- burn treatment
- topical ointment
- composition
- treatment according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 229940100615 topical ointment Drugs 0.000 title claims abstract description 16
- 230000001530 keratinolytic effect Effects 0.000 claims abstract description 9
- 229940124091 Keratolytic Drugs 0.000 claims abstract description 8
- 238000010521 absorption reaction Methods 0.000 claims abstract description 8
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 8
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 230000000887 hydrating effect Effects 0.000 claims abstract description 6
- 230000001172 regenerating effect Effects 0.000 claims abstract description 5
- 230000035876 healing Effects 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- 244000062327 Eupatorium odoratum Species 0.000 claims description 3
- 235000009199 Lamium album Nutrition 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229960005274 benzocaine Drugs 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229940072358 xylocaine Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 241000208690 Hamamelis Species 0.000 claims 2
- 150000001621 bismuth Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 abstract description 7
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 208000028990 Skin injury Diseases 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- 150000000703 Cerium Chemical class 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229910000416 bismuth oxide Inorganic materials 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- TYIXMATWDRGMPF-UHFFFAOYSA-N dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Bi+3].[Bi+3] TYIXMATWDRGMPF-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- -1 silver organometallic compounds Chemical class 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical class C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Definitions
- the present invention relates to the direct treatment of burns by means of a topical burn treatment composition.
- the present invention describes a process to prepare a medicinal formulation in the form of a cream or ointment that, when spread over the injured skin area efficiently promotes the restoration of the skin tissue within a short time, even in cases in which the skin has been severely damaged.
- compositions for topical use are commercially available, said compositions having anaesthetic properties combined with one of the following: bactericidal, anti-inflammatory or hydrating. Said compositions are employed to lessen the pain consequent to the burn, avoid the onset of infection and provide proper hydration conditions leading to the regeneration of the skin structures that have been damaged and dehydrated by intense and localized heat.
- US patent 4500511 describes the preparation of an analgesic and antiinflamatory gel composition employing as the pharmacologically active ingredient 6-chloro-5-cyclohexalindanoic acid, commercially known as Clidanac.
- the principal object of the present invention is to provide a process to prepare a medicinal composition having the form of an ointment or cream, simultaneously comprising active components with bactericidal, analgesic, keratolytic and tissue regeneration activating actions, as well as warding off pathogenic conditions due to infection and furnishing the necessary hydration and activation conditions conducive to restoration of the damaged skin structures.
- Another object of the invention is to provide a medicinal ointment or cream comprising components that enhance the absorption or permeation of the active components in sufficient concentration, as well as a duration of time of contact with the afflicted tissues sufficient for the speedy and efficient regeneration of said tissues.
- It is yet another object of the invention to provide a medicinal ointment or cream composition comprising components that enhance the absorption or permeation of active components in sufficient concentration to achieve local anaesthesia, relieving the pain and the itching that afflict patients suffering from burns. It is a further object of the invention to provide a medicinal ointment or cream comprising aromatic components that impart to the injured patient a pleasant sensation in the course of the recovery.
- the above objects are achieved by means of a composition
- a composition comprising from 8% to 15% by weight of a local anaesthetic, from 1% to 8% by weight of a keratolytic and aromatic compound, from 10% to 40 by weight of a mixture of metallic salt and oxide having bactericidal and regenerative effects, as well as a mixture of natural organic extracts conducive to skin hydration and enhancement of the active components permeation or absorption through the skin barrier. Therefore, in addition to the bactericidal, anaethetic, keratolytic, regeneration activating, hydrating and aromatic actions, the composition provides means that enhance the absorption and/or permeation of the active components thorough the skin.
- a process to prepare a medicinal composition in the form of an ointment or cream comprising the following steps: • mixing the salt and the oxide, such as, for example, zinc chloride, cerium nitrate, bismuth oxide, bismuth subnitrate or zinc oxide, comprising from about 4 to about 10 weight percent of the salt and from about 6 to about 30 weight percent of the oxide, in about 35 to about 55 weight percent fluid hammamelis extract to which about 0,5 to about 2 weight percent wood derived tar such as Archangel or Sweden tar has been previously mixed.
- the oxide such as, for example, zinc chloride, cerium nitrate, bismuth oxide, bismuth subnitrate or zinc oxide
- the above composition may comprise the addition of one or more of the components in ointment form.
- Table II shows the above mentioned characteristics for the four exemplificative embodiments.
- the affected area is first washed with physiological saline solution. Then the ointment is spread so as to cover thoroughly said harmed area, which is then dressed with sterile gauze.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une composition d'onguent s'utilisant en application locale pour traiter les brûlures. Cet onguent, qui a la consistance d'une pommade ou d'une crème, est destiné à soigner les tissus de la peau, et plus particulièrement les blessures infligées à la peau par brûlure. A cet effet, cet onguent provoque une régénération rapide et efficace des zones lésées de la peau. La réalisation préférée de la composition comprend un mélange de différents principes actifs, et notamment un bactéricide, un anesthésique, un kératolytique, un hydratant, un activateur de la régénération tissulaire, de l'absorption tissulaire et de la perméabilité tissulaire, ainsi qu'un agent aromatisant.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR9604441A BR9604441A (pt) | 1996-10-23 | 1996-10-23 | Pomada para queimaduras |
| PCT/BR1998/000031 WO1999065526A1 (fr) | 1996-10-23 | 1998-06-15 | Composition d'onguent s'utilisant en application locale pour traiter les brulures |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR9604441A BR9604441A (pt) | 1996-10-23 | 1996-10-23 | Pomada para queimaduras |
| PCT/BR1998/000031 WO1999065526A1 (fr) | 1996-10-23 | 1998-06-15 | Composition d'onguent s'utilisant en application locale pour traiter les brulures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999065526A1 true WO1999065526A1 (fr) | 1999-12-23 |
Family
ID=25664775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR1998/000031 WO1999065526A1 (fr) | 1996-10-23 | 1998-06-15 | Composition d'onguent s'utilisant en application locale pour traiter les brulures |
Country Status (2)
| Country | Link |
|---|---|
| BR (1) | BR9604441A (fr) |
| WO (1) | WO1999065526A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008035085A1 (fr) * | 2006-09-22 | 2008-03-27 | Syntopix Limited | Formulations antimicrobiennes |
| US20150132240A1 (en) * | 2010-11-15 | 2015-05-14 | Barry Knapp | Topical Composition And Method For Skin Treatment |
-
1996
- 1996-10-23 BR BR9604441A patent/BR9604441A/pt unknown
-
1998
- 1998-06-15 WO PCT/BR1998/000031 patent/WO1999065526A1/fr active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| HELWIG H., OTTO H. H., Arzneimittel, 8th Edition, Vol. I, Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1992, pages 22-2 to 22-17 and 22-29 to 22-31 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008035085A1 (fr) * | 2006-09-22 | 2008-03-27 | Syntopix Limited | Formulations antimicrobiennes |
| US20150132240A1 (en) * | 2010-11-15 | 2015-05-14 | Barry Knapp | Topical Composition And Method For Skin Treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9604441A (pt) | 1998-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5266318A (en) | Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed | |
| CN108853312B (zh) | 聚桂醇外用凝胶及其制备方法 | |
| US4296104A (en) | Therapeutic dimethyl sulfoxide composition and methods of use | |
| Bilsel et al. | Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation | |
| US4604384A (en) | Pharmaceutical gel composition | |
| US6780439B2 (en) | Wound treatment solution and method for using same | |
| JPS6061529A (ja) | 皮膚外傷治療用組成物及びその治療方法 | |
| US20040147534A1 (en) | Topical composition and method for treating occlusive wounds | |
| US6465514B1 (en) | Methods and compositions for the promotion of hair growth | |
| RU2177314C2 (ru) | Состав с антисептическими, репаративными и болеутоляющими свойствами | |
| US5278172A (en) | Method and composition for treating tendon or joint inflammation using a vasodilator | |
| HOLDER et al. | The use of urea in the treatment of infected wounds | |
| WO1999065526A1 (fr) | Composition d'onguent s'utilisant en application locale pour traiter les brulures | |
| RU2416425C1 (ru) | Масло противопролежневое | |
| JPH08500343A (ja) | セシウムイオンを用いた治療方法 | |
| RU2145497C1 (ru) | Средство для лечения гнойно-некротических процессов | |
| US7438937B2 (en) | Topical burn composition containing Mentha haplocalyx and one or both of Aloe vera and recombinant human epidermal growth factor | |
| RU2127110C1 (ru) | Средство для лечения ожогов | |
| ES2235443T3 (es) | Composiciones farmaceuticas topicas para curar heridas, que constan de borneol y subgalato de bismuto. | |
| RU2063762C1 (ru) | Мазь для лечения кожных заболеваний и трофических язв | |
| WO2018188197A1 (fr) | Médicament antibactérien et anti-inflammatoire et son procédé de préparation | |
| AU558482B2 (en) | Pharmaceutical gel composition | |
| KR100289906B1 (ko) | 피부용조성물 | |
| RU2223751C1 (ru) | Лекарственное средство для лечения ожогов | |
| RU2163485C1 (ru) | Способ о.ф. и с.а. лапиных лечения ожогов и других поражений кожи с использованием препарата "дарина" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |